Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome
- PMID: 24561134
- PMCID: PMC4018823
- DOI: 10.1016/j.jacc.2014.01.031
Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome
Abstract
Objectives: The aim of this study was to test the hypothesis that rare variants are associated with drug-induced long QT interval syndrome (diLQTS) and torsades de pointes.
Background: diLQTS is associated with the potentially fatal arrhythmia torsades de pointes. The contribution of rare genetic variants to the underlying genetic framework predisposing to diLQTS has not been systematically examined.
Methods: We performed whole-exome sequencing on 65 diLQTS patients and 148 drug-exposed control subjects of European descent. We used rare variant analyses (variable threshold and sequence kernel association test) and gene-set analyses to identify genes enriched with rare amino acid coding (AAC) variants associated with diLQTS. Significant associations were reanalyzed by comparing diLQTS patients with 515 ethnically matched control subjects from the National Heart, Lung, and Blood Grand Opportunity Exome Sequencing Project.
Results: Rare variants in 7 genes were enriched in the diLQTS patients according to the sequence kernel association test or variable threshold compared with drug-exposed controls (p < 0.001). Of these, we replicated the diLQTS associations for KCNE1 and ACN9 using 515 Exome Sequencing Project control subjects (p < 0.05). A total of 37% of the diLQTS patients also had 1 or more rare AAC variants compared with 21% of control subjects (p = 0.009), in a pre-defined set of 7 congenital long QT interval syndrome (cLQTS) genes encoding potassium channels or channel modulators (KCNE1, KCNE2, KCNH2, KCNJ2, KCNJ5, KCNQ1, AKAP9).
Conclusions: By combining whole-exome sequencing with aggregated rare variant analyses, we implicate rare variants in KCNE1 and ACN9 as risk factors for diLQTS. Moreover, diLQTS patients were more burdened by rare AAC variants in cLQTS genes encoding potassium channel modulators, supporting the idea that multiple rare variants, notably across cLQTS genes, predispose to diLQTS.
Keywords: adverse drug event; exome; genetics; long QT interval syndrome; torsade des pointes.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Drug-induced long QT syndrome and exome sequencing: Chinese shadows link past and future.J Am Coll Cardiol. 2014 Apr 15;63(14):1438-40. doi: 10.1016/j.jacc.2014.01.030. Epub 2014 Feb 19. J Am Coll Cardiol. 2014. PMID: 24561140 No abstract available.
Similar articles
-
A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes.Circ Cardiovasc Genet. 2012 Feb 1;5(1):91-9. doi: 10.1161/CIRCGENETICS.111.960930. Epub 2011 Nov 18. Circ Cardiovasc Genet. 2012. PMID: 22100668 Free PMC article.
-
Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes.Pharmacogenomics J. 2013 Aug;13(4):325-9. doi: 10.1038/tpj.2012.14. Epub 2012 May 15. Pharmacogenomics J. 2013. PMID: 22584458 Free PMC article.
-
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.Circulation. 2002 Apr 23;105(16):1943-8. doi: 10.1161/01.cir.0000014448.19052.4c. Circulation. 2002. PMID: 11997281
-
The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants.Pharmacogenomics. 2022 Jun;23(9):543-557. doi: 10.2217/pgs-2022-0027. Epub 2022 Jun 14. Pharmacogenomics. 2022. PMID: 35698903 Free PMC article. Review.
-
Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.J Am Coll Cardiol. 2016 Apr 5;67(13):1639-1650. doi: 10.1016/j.jacc.2015.12.063. J Am Coll Cardiol. 2016. PMID: 27150690 Review.
Cited by
-
Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation.Nat Genet. 2017 Jun;49(6):946-952. doi: 10.1038/ng.3843. Epub 2017 Apr 17. Nat Genet. 2017. PMID: 28416818 Free PMC article.
-
Examining rare and low-frequency genetic variants previously associated with lone or familial forms of atrial fibrillation in an electronic medical record system: a cautionary note.Circ Cardiovasc Genet. 2015 Feb;8(1):58-63. doi: 10.1161/CIRCGENETICS.114.000718. Epub 2014 Nov 19. Circ Cardiovasc Genet. 2015. PMID: 25410959 Free PMC article.
-
Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?Addiction. 2017 Dec;112(12):2086-2094. doi: 10.1111/add.13818. Epub 2017 Apr 21. Addiction. 2017. PMID: 28431457 Free PMC article. Review.
-
Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century.J Physiol. 2016 Dec 1;594(23):6893-6908. doi: 10.1113/JP272015. Epub 2016 Jun 9. J Physiol. 2016. PMID: 27060987 Free PMC article.
-
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).Clin Cancer Res. 2018 Oct 1;24(19):4734-4744. doi: 10.1158/1078-0432.CCR-17-1523. Epub 2018 Jun 5. Clin Cancer Res. 2018. PMID: 29871907 Free PMC article.
References
-
- Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 2001;104:569–80. - PubMed
-
- De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 2002;25:263–86. - PubMed
-
- Roden DM. Drug-induced prolongation of the QT interval. The New England journal of medicine. 2004;350:1013–22. - PubMed
-
- Kannankeril PJ, Roden DM, Norris KJ, Whalen SP, George AL, Jr., Murray KT. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm. 2005;2:134–40. - PubMed
-
- Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 GM97119/GM/NIGMS NIH HHS/United States
- P30 EY08126/EY/NEI NIH HHS/United States
- T32 GM007569/GM/NIGMS NIH HHS/United States
- U19HL065962/HL/NHLBI NIH HHS/United States
- 16FTF30130005/AHA_/American Heart Association-American Stroke Association/United States
- P30 EY008126/EY/NEI NIH HHS/United States
- P30 CA068485/CA/NCI NIH HHS/United States
- GM07569/GM/NIGMS NIH HHS/United States
- U01 GM097119/GM/NIGMS NIH HHS/United States
- P30 CA68485/CA/NCI NIH HHS/United States
- U19 HL065962/HL/NHLBI NIH HHS/United States
- U19HL069757/HL/NHLBI NIH HHS/United States
- G20 RR030956/RR/NCRR NIH HHS/United States
- U01 HG006378/HG/NHGRI NIH HHS/United States
- U19 HL069757/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical